Cadent Therapeutics initiates Phase 1 Clinical study for CAD-1883
Cadent Therapeutics which is a precision neuroscience company developing novel medicines to restore movement and cognitive function in patients with neurological and psychiatric disease asserted the initiation of a Phase 1 Clinical Study for its lead product candidate CAD-1883.
The compound is a selective first-in-class positive allosteric modulator of the small conductance calcium-activated potassium (SK) channel.
Michael Curtis, PhD, President and CEO of Cadent Therapeutics said “We have shown that allosteric modulation of the SK channel restores cadence to neuronal firing and is efficacious in disease models of ataxia and tremor. Our hope is that by precisely tuning dysregulated neuronal firing, we can reduce disability and restore motor function in patients with spinocerebellar ataxia and essential tremor.”
Cadent Therapeutics leverages recent advances in scientific understanding, functional biomarker research , patient selection and innovations in disability measurements to advance breakthrough medicines for neurological and neuropsychiatric diseases.
The company is rapidly advancing its pipeline of therapies to treat spinocerebellar ataxia, essential tremor and schizophrenia.
In patients with spinocerebellar ataxia and essential tremor, the firing pattern of neurons in the cerebellum has become dysregulated, resulting in the loss of motor control, impacting mobility and fine motor function. By changing the calcium sensitivity of SK channels, CAD-1883 causes potassium current to flow at lower calcium concentrations, restoring neuronal firing regularity and improving motor function.